Market research
CBOC.F Celsion Corporation
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 2M
- P/E ratio
- Not available
- Analyst target
- 3
- Dividend yield
- 0.0%
- Beta
- 1.9
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 2M
- P/E ratio
- Not available
- Analyst target
- 3
- Dividend yield
- 0.0%
- Beta
- 1.9
About
About Celsion Corporation
Celsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of directed chemotherapies, DNA-mediated immunotherapy, and vaccines. Its lead product candidate is ThermoDox, a liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for the treatment of primary liver cancer. The company is also developing GEN-1, a DNA-based immunotherapeutic product, which is in Phase II clinical trials for the localized treatment of ovarian cancers. Celsion Corporation was founded in 1982 and is based in Lawrenceville, New Jersey.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the CBOC.F discussion.
5 years, 5 months ago
Celsion Corporation is currently in a long term downtrend where the price is trading 0.4% below its 200 day moving average.
From a valuation standpoint, the stock is 93.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 88.4.
Celsion Corporation's total revenue sank by 0.0% to $125K since the same quarter in the previous year.
Its net income has increased by 2.9% to $-3M since the same quarter in the previous year.
Finally, its free cash flow grew by 33.6% to $-4M since the same quarter in the previous year.
Based on the above factors, Celsion Corporation gets an overall score of 3/5.